Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors.

Phase 1

Epigenetix, Inc.